Review
Medicine, General & Internal
Han Chen, Xin-Zhu Li, Jia-Qing Chen, Tian-Shu Ren, Ying-Shi Zhang, Yi-Nuo Wang, Qing-Chun Zhao
Summary: This study conducted a network meta-analysis to evaluate the clinical efficacy and safety of 4 weekly formulations of GLP-1RAs. The results showed that the different doses of GLP-1RAs had differential glycemic control, with Semaglutide 2.0mg exhibiting the best performance in comprehensively lowering blood sugar.
Article
Medicine, General & Internal
Julio Rosenstock, Carol Wysham, Juan P. Frias, Shizuka Kaneko, Clare J. Lee, Laura Fernandez Lando, Huzhang Mao, Xuewei Cui, Chrisanthi A. Karanikas, Vivian T. Thieu
Summary: Tirzepatide demonstrated significant improvements in glycemic control and body weight without increasing the risk of hypoglycemia. The safety profile was consistent with GLP-1 receptor agonists, suggesting a potential monotherapy use for the treatment of type 2 diabetes.
Article
Endocrinology & Metabolism
Tetsuhiko Sato, Yoshinori Azuma, Chikafumi Ozone, Mikako Okazaki, Asami Takeda, Manabu Okada, Kenta Futamura, Takahisa Hiramitsu, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai
Summary: This retrospective cohort study found that the use of GLP-1 receptor agonists in type 2 diabetes patients after kidney transplantation was associated with a lower risk of sustained reduction in kidney function.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Integrative & Complementary Medicine
Li Qiang, Yang Qimeng, Han Jing, Liu Xiaohan, Fu Junjie, Yin Jian
Summary: Peptide dual agonists that target both GLP-1R and GCGR receptors have emerged as potential therapeutics for treating type 2 diabetes with obesity. O-GlcNAcylation was shown to improve the stability of a dual GLP-1R/GCGR agonist, leading to significant weight loss and hypoglycemic effects.
CHINESE JOURNAL OF NATURAL MEDICINES
(2022)
Review
Clinical Neurology
David M. Williams, Michael Atkinson, Marc Evans
Summary: Stroke is a common and serious complication in people with type 2 diabetes. It is important to understand the underlying mechanisms and explore potential treatments to reduce the risk and improve outcomes for these patients.
Article
Chemistry, Medicinal
Neng Jiang, Lin Jing, Qing Li, Sibiao Su, Qimeng Yang, Feng Zhou, Xinyu Chen, Jing Han, Chunli Tang, Weizhong Tang
Summary: Dual activation of the glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) can potentially lead to effective therapy for diabetes and obesity. Novel peptides with dual activity on GLP-1R and GCGR were discovered through rational design, with xGLP/GCG-15 showing promising anti-obesity and anti-diabetic effects in preclinical studies.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Clinical Neurology
Ronald M. Goldenberg, Alice Y. Y. Cheng, Tess Fitzpatrick, Jeremy D. Gilbert, Subodh Verma, Julia J. Hopyan
Summary: People with diabetes face higher stroke risks and poorer outcomes. GLP-1RAs have been shown to reduce stroke risk in individuals with type 2 diabetes. This study provides evidence supporting the use of GLP-1RAs for stroke reduction and offers practical resources for neurologists considering this treatment.
Review
Endocrinology & Metabolism
Zeyu Xie, Jia Hu, Hangye Gu, Mengting Li, Jisheng Chen
Summary: This study conducted a network meta-analysis to evaluate the effectiveness and safety of 10 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) combined with metformin in patients with type 2 diabetes, and aimed to provide evidence-based support and reference for clinical treatment selection.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Endocrinology & Metabolism
J. D. Watkins, S. Carter, G. Atkinson, F. Koumanov, J. A. Betts, J. J. Holst, J. T. Gonzalez
Summary: This systematic review aims to investigate the effect of type 2 diabetes (T2D) on GLP-1 secretion and explore potential moderators. The findings show that there is minimal and inconsistent difference in GLP-1 secretion between individuals with T2D and without T2D.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2023)
Article
Endocrinology & Metabolism
Xueyuan Guo, Caihua Sang, Ribo Tang, Chenxi Jiang, Songnan Li, Nian Liu, Deyong Long, Xin Du, Jianzeng Dong, Changsheng Ma
Summary: This meta-analysis aimed to assess the effects of GLP-1RAs on major coronary events in patients with T2DM. The results showed that GLP-1RAs can reduce the risk of myocardial infarction, especially human-based and once-weekly GLP-1RAs. However, no significant benefit was observed for hospitalization for unstable angina or coronary revascularization.
DIABETES OBESITY & METABOLISM
(2023)
Review
Chemistry, Medicinal
Dihe Cheng, Shuo Yang, Xue Zhao, Guixia Wang
Summary: This article reviews the molecular mechanisms and potential effects of GLP-1 RA in neurodegenerative diseases, particularly diabetes-related Alzheimer's disease and Parkinson's disease.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Biochemistry & Molecular Biology
Stelia Ntika, Linda M. Tracy, Anders Franco-Cereceda, Hanna M. Bjorck, Camilla Krizhanovskii
Summary: The study suggests that reduced prevalence of thoracic aortic aneurysm in type 2 diabetes patients may be related to the regulatory effects of GLP-1 and Sdc-1 in vascular tissue.
Review
Endocrinology & Metabolism
Sisi Luan, Wenke Cheng, Chenglong Wang, Jianhong Gong, Jianbo Zhou
Summary: Through a systematic review and meta-analysis, it was found that GLP-1 analogs have no significant effects on the general cognitive functioning of patients with type 2 diabetes, but may be beneficial for patients younger than 65 years or those without a history of cardio-cerebrovascular diseases.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Medicine, Research & Experimental
Yawen Jiang, Jia Liu, Xin Chen, Wenying Yang, Weiping Jia, Jing Wu
Summary: The study evaluated the effects of GLP-1 receptor agonists on clinical and safety outcomes using network meta-analysis. Findings indicated that different GLP-1RA regimens had differential effects on glycemic control and cardiometabolic indicators, while showing comparable safety profiles.
ADVANCES IN THERAPY
(2021)
Review
Endocrinology & Metabolism
Vikas S. Sridhar, Christine P. Limonte, Per-Henrik Groop, Hiddo J. L. Heerspink, Richard E. Pratley, Peter Rossing, Jay S. Skyler, David Z. I. Cherney
Summary: The current management of CKD in type 1 diabetes focuses on blood sugar control, inhibiting the renin-angiotensin system and optimizing risk factors. However, individuals with type 1 diabetes and CKD still face elevated risks for kidney and cardiovascular events. Novel therapies used in type 2 diabetes, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists, have shown potential kidney and heart protection. Applying these therapies to individuals with type 1 diabetes for the prevention of CKD is of great importance.
Article
Engineering, Biomedical
Yu-Jeong Kim, Su Young Chae, Cheng-Hao Jin, M. Sivasubramanian, Sohee Son, Ki Young Choi, Dong-Gyu Jo, Kwangmeyung Kim, Ick Chan Kwon, Kang Choon Lee, Jae Hyung Park
Article
Biochemistry & Molecular Biology
Song Cui, Yong-Hoon Kim, Cheng-Hao Jin, Sang Kook Kim, Man-hee Rhee, Oh-Shin Kwon, Byung Jo Moon
Article
Chemistry, Multidisciplinary
Cheng-Hao Jin, Su Young Chae, Sohee Son, Tae Hyung Kim, Key An Um, Yu Seok Youn, Seulki Lee, Kang Choon Lee
JOURNAL OF CONTROLLED RELEASE
(2009)
Article
Chemistry, Multidisciplinary
Su Young Chae, Cheng-Hao Jin, Jae Hee Shin, Sohee Son, Tae Hyung Kim, Seulki Lee, Yu Seok Youn, Youngro Byun, Myung-Shik Lee, Kang Choon Lee
JOURNAL OF CONTROLLED RELEASE
(2010)
Article
Pharmacology & Pharmacy
Cheng-Hao Jin, Su Young Chae, Tae Hyung Kim, Han-Kwang Yang, Eun Young Lee, Yeong Wook Song, Dong-Gyu Jo, Kang Choon Lee
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2010)
Article
Oncology
Su Young Chae, Tae Hyung Kim, Kyeongsoon Park, Cheng-Hao Jin, Sohee Son, Seulki Lee, Yu Seok Youn, Kwangmeyung Kim, Dong-Gyu Jo, Ick Chan Kwon, Xiaoyuan Chen, Kang Choon Lee
MOLECULAR CANCER THERAPEUTICS
(2010)
Article
Biochemistry & Molecular Biology
Wan-Ting Xu, Gui-Nan Shen, Ying-Hua Luo, Xian-Ji Piao, Jia-Ru Wane, Hao Wang, Yi Zhang, Jin-Qian Li, Yu-Chao Feng, Yu Zhang, Tong Zhang, Shi-Nong Wang, Chang-Yuan Wang, Cheng-Hao Jin
CHEMICO-BIOLOGICAL INTERACTIONS
(2019)
Article
Oncology
Yan-Qing Zang, Yan-Yu Feng, Ying-Hua Luo, Yu-Qing Zhai, Xue-Ying Ju, Yu-Chao Feng, Ya-Nan Sheng, Jia-Ru Wang, Chang-Qing Yu, Cheng-Hao Jin
MOLECULAR MEDICINE REPORTS
(2019)
Article
Mathematical & Computational Biology
Bocui Song, Xue Shen, Shuang Zhang, Rui Zhao, Yanhong Wang, Mengmeng Jiang, Min Liu, Qian Chen, Yuqi Li, Baolei Huang, Chenghao Jin, Chunyu Tong
Summary: This study evaluated the immunomodulatory effects of fisetin in an allergic contact dermatitis (ACD) model, showing that fisetin significantly improved inflammation in ACD mice and restored the balance of Th17/Treg cells.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
(2022)
Article
Chemistry, Medicinal
Tong Han, Chunyu Jiang, Xing Wei, Meilin Sheng, Qin Xie, Jiqiang Zhang, Yongyi Zhang, Chenghao Jin
Summary: A unique series of amide-scutellarin derivatives were synthesized and evaluated for their antiproliferative and neuroprotective activities. Some of the compounds showed significant antitumor and neuroprotective effects.
MEDICINAL CHEMISTRY RESEARCH
(2022)
Article
Chemistry, Medicinal
Tong Zhang, Guo-Yan Liu, Jing-Long Cao, Yan-Nan Li, Hui Xue, Hai-Tao Wu, Cheng-Hao Jin
Summary: In this study, the antitumor effects of Peimine (PM) on gastric cancer cells were investigated. The results showed that PM reduced the activity of gastric cancer cells, induced apoptosis, disrupted mitochondrial function, and regulated several signaling pathways and cell migration.
DRUG DEVELOPMENT RESEARCH
(2022)
Article
Food Science & Technology
Cheng-Hao Jin, Ung Yang, Song-Hee Kim, Jae-Won Ryu, Jae-Chang Lee, Dong-Seok Lee, Tae-Hoon Lee
FOOD SCIENCE AND BIOTECHNOLOGY
(2007)
Article
Biotechnology & Applied Microbiology
Yu Seok Youn, Min Jae Shin, Su Young Chae, Cheng-Hao Jin, Tae Hyung Kim, Kang Choon Lee
BIOTECHNOLOGY LETTERS
(2007)